Comparative Pharmacology
Head-to-head clinical analysis: GLYCORT versus TIOTROPIUM BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLYCORT versus TIOTROPIUM BROMIDE.
GLYCORT vs TIOTROPIUM BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; modulates gene expression to produce anti-inflammatory and immunosuppressive effects.
Tiotropium bromide is a long-acting, competitive, and reversible muscarinic receptor antagonist (anticholinergic). It binds preferentially to M3 receptors in the smooth muscle of the bronchi, inhibiting acetylcholine-mediated bronchoconstriction and mucus secretion, leading to prolonged bronchodilation.
Intravenous: 2 mg/kg every 12 hours; Oral: 20 mg twice daily.
Inhalation (oral): 18 mcg once daily via HandiHaler; or 2.5 mcg (2 puffs) once daily via Respimat inhaler.
None Documented
None Documented
3.5 hours (terminal); prolonged in hepatic impairment (up to 8 hours) and severe renal impairment (up to 6 hours)
Terminal elimination half-life: 5–6 days (inhalation). Longer half-life allows once-daily dosing. Steady-state reached in 2–3 weeks.
Renal: 70% as unchanged drug; biliary/fecal: 25% (metabolites); 5% other
Primarily renal: 14% of dose excreted unchanged in urine; remainder as inactive metabolites via biliary/fecal (70%) and renal (30% total).
Category C
Category A/B
Anticholinergic
Anticholinergic